Delova Biotech

Focus: Delova Biotech is a China-based biotechnology company specializing in small molecule analgesics, primarily focused on musculoskeletal indications. The company operates a commercial portfolio of generic and branded pain management products with limited disclosed scale metrics.

Musculoskeletal

Profile data last refreshed 13h ago · AI intelligence enriched 2w ago

Open Jobs

About Delova Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Delova Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

QAMZOVA

Musculoskeletal

Growth13.9yr

Only growth-stage asset; COX-2 inhibitor with 16+ years of LOE exclusivity provides revenue predictability in musculoskeletal market.

Help build intelligence for Delova Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

QAMZOVA (meloxicam) is in growth phase with LOE protection until 2040, providing stable revenue visibility in a defined therapeutic area.
Established commercial portfolio including post-LOE assets (celecoxib, propofol) demonstrates operational maturity in regulatory and manufacturing.
China-based operations offer exposure to one of the world's fastest-growing pharmaceutical markets with expanding musculoskeletal disease prevalence.

Watch Out For

No active pipeline programs (0 Phase 1/2/3 trials) signals limited innovation trajectory and R&D investment—career growth in drug development is constrained.
Zero open job positions at the time of this analysis indicates no active hiring and potentially limited vertical mobility.
Critical missing data on funding, employee count, and financials prevents assessment of company stability, cash runway, and compensation competitiveness.
Heavy reliance on generic/post-LOE products with meloxicam as only growth-stage asset creates vulnerability to pricing pressure and competitive generics.

Generated by Claude from Delova Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CELECOXIB

Rheumatoid Arthritis

Post-LOE

Post-LOE generic COX-2 inhibitor competing in mature market; indicates commodity-phase portfolio management.

PROPOFOL

General Anesthetic

Post-LOE

Post-LOE ANDA product in anesthesia; portfolio diversification away from musculoskeletal but no growth potential.